Get the Stockscreener App
9.74
0.52%
0.05
Oric Pharmaceuticals Inc stock is traded at $9.74, with a volume of 531.44K.
It is up +0.52% in the last 24 hours and down -12.65% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$9.69
Open:
$9.78
24h Volume:
531.44K
Relative Volume:
0.40
Market Cap:
$945.98M
Revenue:
-
Net Income/Loss:
$-119.87M
P/E Ratio:
-5.3812
EPS:
-1.81
Net Cash Flow:
$-109.90M
1W Performance:
+0.83%
1M Performance:
-12.65%
6M Performance:
+26.82%
1Y Performance:
+5.98%
1-Day Range:
$9.645
$10.14
1-Week Range:
$9.3214
$10.14
52-Week Range:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.74 | 961.52M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Equities Analysts Offer Predictions for ORIC Q3 Earnings - MarketBeat
ORIC Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
ORIC Pharmaceuticals: Strategic Talent and Pipeline Innovation Drive Long-Term Oncology Outperformance - AInvest
ORIC Pharmaceuticals appoints Kevin Brodbeck as chief technical officer By Investing.com - Investing.com Nigeria
Oric Pharmaceuticals appoints Kevin Brodbeck CTO - TipRanks
ORIC Pharmaceuticals appoints Kevin Brodbeck as chief technical officer - Investing.com
ORIC Pharmaceuticals Appoints Kevin Brodbeck, PhD, as Chief Technical Officer to Support Advancement into Late-Stage Clinical Development - Quiver Quantitative
Oric pharmaceuticals taps Kevin Brodbeck as chief technical officer - MarketScreener
ORIC® Pharmaceuticals Expands Leadership Team with the Appointme - GuruFocus
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - GlobeNewswire
Former Deciphera Tech Chief Joins ORIC Pharmaceuticals to Lead Phase 3 Development of Two Cancer Drugs - Stock Titan
HC Wainwright & Co. Lowers ORIC Pharmaceuticals' Price Target to $19.00, Maintains "Buy" Rating - AInvest
Volume spikes in ORIC Pharmaceuticals Inc. stock – what they mean2025 Biggest Moves & Verified Entry Point Detection - Newser
Using economic indicators to assess ORIC Pharmaceuticals Inc. potential2025 Volatility Report & Daily Growth Stock Investment Tips - Newser
Oric Pharmaceuticals (NASDAQ:ORIC) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
How to manage a losing position in ORIC Pharmaceuticals Inc.Quarterly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Visualizing ORIC Pharmaceuticals Inc. stock with heatmaps2025 Technical Overview & Daily Stock Trend Watchlist - Newser
Signal strength of ORIC Pharmaceuticals Inc. stock in tech scannersWeekly Trend Summary & Free Technical Confirmation Trade Alerts - Newser
Visual trend scoring systems applied to ORIC Pharmaceuticals Inc.Trade Exit Report & Growth Focused Entry Reports - Newser
Wedbush Predicts Weaker Earnings for Oric Pharmaceuticals - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded to Hold at Zacks Research - MarketBeat
Can ORIC Pharmaceuticals Inc. rally from current levels2025 Year in Review & Growth Oriented Trade Recommendations - Newser
What data driven models say about ORIC Pharmaceuticals Inc.’s futureJuly 2025 Catalysts & Consistent Income Trade Recommendations - Newser
Will ORIC Pharmaceuticals Inc. see short term momentumDividend Hike & Safe Capital Growth Tips - Newser
Market reaction to ORIC Pharmaceuticals Inc.’s recent newsWeekly Market Report & Fast Moving Stock Watchlists - Newser
Can volume confirm reversal in ORIC Pharmaceuticals Inc.2025 Sector Review & Risk Adjusted Buy/Sell Alerts - Newser
Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials - MSN
ORIC Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Trade Review & Real-Time Volume Analysis - Newser
Will a bounce in ORIC Pharmaceuticals Inc. offer an exitTrend Reversal & Reliable Entry Point Alerts - Newser
Chart Analysts Warn of Resistance Near ORIC Pharmaceuticals Inc. PriceJuly 2025 Levels & Community Verified Trade Signals - newsyoung.net
JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $19.00 Price Target at HC Wainwright - MarketBeat
Q3 EPS Estimates for Oric Pharmaceuticals Reduced by Wedbush - Defense World
Will ORIC Pharmaceuticals Inc. continue its uptrend2025 Price Momentum & Community Driven Trade Alerts - Newser
HC Wainwright Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $19.00 - Defense World
Oric Pharmaceuticals: Promising Future with Key Trials and Financial Stability Underpinning Buy Rating - TipRanks
Oric Pharmaceuticals' (ORIC) Buy Rating Reiterated at Guggenheim - MarketBeat
XTX Topco Ltd Cuts Stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at JPMorgan Chase & Co. - Defense World
Guggenheim Reaffirms “Buy” Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - Defense World
What makes ORIC Pharmaceuticals Inc. stock price move sharplyEarnings Recap Summary & Fast Entry Momentum Trade Alerts - Newser
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $12 to $23 - 富途牛牛
How to forecast ORIC Pharmaceuticals Inc. trends using time series2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Jefferies Reiterates Buy Rating on Oric Pharmaceuticals with $23 Price Target. - AInvest
Guggenheim Reaffirms Buy Rating for ORIC Pharmaceuticals with $18 Target Price. - AInvest
Contineum Therapeutics shares fall 1.04% intraday after ORIC Pharmaceuticals reports positive clinical data and financing activity. - AInvest
Moving Average Trends for ORIC Pharmaceuticals Inc. Stock: What They IndicateWeekly Risk Report & Free Risk Controlled Daily Trade Plans - Newser
Guggenheim Reiterates Buy Rating for ORIC Pharmaceuticals | ORIC Stock News - GuruFocus
Guggenheim Keeps Buy Rating, Raises PT for ORIC Pharmaceuticals to $18. - AInvest
ORIC Pharmaceuticals stock price target raised to $23 by Jefferies - Investing.com Canada
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Jun 24 '25 |
Sale |
10.50 |
32,466 |
341,039 |
68,317 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 23 '25 |
Sale |
10.00 |
1,034 |
10,344 |
100,783 |
| You Angie | Director |
Jun 20 '25 |
Buy |
9.39 |
26,597 |
249,669 |
26,597 |
| You Angie | Director |
Jun 23 '25 |
Buy |
9.43 |
1,403 |
13,230 |
28,000 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 12 '25 |
Sale |
10.00 |
300 |
3,000 |
101,817 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 11 '25 |
Sale |
10.01 |
2,976 |
29,777 |
102,117 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 10 '25 |
Sale |
10.00 |
324 |
3,240 |
105,093 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 06 '25 |
Sale |
10.01 |
2,600 |
26,021 |
104,164 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 09 '25 |
Sale |
10.00 |
300 |
3,000 |
103,864 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):